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Abstract
Mast cells are implicated in the pathogenesis of inflammatory and autoimmune diseases. However, this notion based on
studies in mast cell-deficient mice is controversial. We therefore established an in vivo model for hyperactive mast cells by
specifically ablating the NF-kB negative feedback regulator A20. While A20 deficiency did not affect mast cell degranulation,
it resulted in amplified pro-inflammatory responses downstream of IgE/FceRI, TLRs, IL-1R, and IL-33R. As a consequence
house dust mite- and IL-33-driven lung inflammation, late phase cutaneous anaphylaxis, and collagen-induced arthritis were
aggravated, in contrast to experimental autoimmune encephalomyelitis and immediate anaphylaxis. Our results provide in
vivo evidence that hyperactive mast cells can exacerbate inflammatory disorders and define diseases that might benefit
from therapeutic intervention with mast cell function.
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Introduction
Mast cells are innate immune cells that localize preferentially to
vascularized tissues at the host-environment barrier. Through their
high-affinity IgE receptor (FceRI) they can capture circulating IgE
and are hence primed to degranulate and produce cytokines upon
antigen encounter. Mast cells store large amounts of histamine,
heparin, and various proteases, which they release within minutes
during degranulation. In contrast, the release of pro-inflammatory
lipid mediators and most cytokines requires de novo synthesis upon
activation [1,2]. Mast cells are also equipped with a range of cell
surface receptors allowing them to sense microbial invasion,
inflammation, and tissue damage, among them several TLRs, the
IL-1R, and the receptor for the alarmin IL-33, the IL-33R.
Engagement of these receptors initiates a pro-inflammatory gene
expression program via NF-kB transcription factors [1,3,4].
More than 100 years after their discovery, the physiological
roles of mast cells in health and disease remain heavily disputed
[5]. It is widely accepted that they are central mediators of IgE-
dependent allergic responses, which can cause life-threatening
anaphylactic shock in susceptible individuals [2]. These deleterious
mast cell properties could be overshooting, misdirected responses
originally designed as components of allergic host defense against
environmental irritants, noxious foreign substances, and enven-
omation [6]. Although these functions might explain the
evolutionary pressure that led to the development and preserva-
tion of mast cells, it is generally believed that further protective
properties await identification. Furthermore, the observation that
human patients suffering from asthma, allergic rhinitis, atopic
dermatitis, and autoimmune and malignant disorders consistently
contained mast cell accumulations at affected locations indicated a
role for mast cells in these diseases [3,7].
Mouse strains lacking mast cells due to different loss-of-function
mutations in the receptor tyrosine kinase c-Kit were instrumental
to elucidate mast cell in vivo functions. However, in the context of
autoimmune, inflammatory, allergic, and malignant disease studies,
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these mouse strains often yielded conflicting results, presumably due
to additional effects of c-Kit deficiency [5]. Moreover, recent experi-
ments employing novel Kit-independent mast cell-deficient mouse
models have challenged some of their initially proposed functions
[8–10]. Regardless of the particular model, loss-of-function approaches
describe the consequences of absent function, which is not always
inversely correlated with excessive function, and functional com-
pensation by other cell types can be a problem. We aimed to
establish a new mouse strain modeling gain-of-function of inflam-
matory mast cell responses, as they are at the center of controversy.
In various immune lineages, the ubiquitin-editing enzyme and
NF-kB negative feedback regulator A20 (also known as Tnfaip3) is
critical for the prevention of inflammation and autoimmunity [11–
16]. Polymorphisms in the A20 gene locus or its binding partner
TNIP1 are significantly associated with a number of human
inflammatory and autoimmune conditions [17,18] and in case of
TNIP1 also with asthma [19]. Therefore, we postulated that A20
deficiency in mast cells should provide an ideal genetic model
system to address their pro-inflammatory properties in a gain-of-
function approach. We employed conditional gene ablation to
demonstrate that A20 restricts NF-kB activation downstream of the
IgE:FceRI module, TLRs, the IL-1R, and the IL-33R in mast cells.
Exaggerated signaling from these receptors to NF-kB strongly
enhanced mast cell pro-inflammatory responses, but did not affect
degranulation. The presence of these hyperactive inflammatory
mast cells exacerbated late phase cutaneous anaphylaxis reactions,
allergic lung, and autoimmune joint inflammation. Our findings
are, to our knowledge, the first direct demonstration that enhanced
inflammatory mast cell responses can contribute to disease pathology.
Results
A20 Is a Negative Regulator of TLR-, IL-33R-, and IgE/
FceRI-Induced NF-kB Activation in Mast Cells
Upon priming with IgE and subsequent aggregation, the mast
cell FceRI activates NF-kB in a similar way to B and T cell antigen
receptors [20], whereas the receptor for IL-33 initiates signaling
cascades analogous to TLR and IL-1R engagement via MyD88
and TRAF6 [4]. We thus hypothesized that in analogy with other
immune cells [18], induced expression of A20 could restrict NF-kB
activation downstream of the IgE/FceRI module and the IL-33R,
as well as the IL-1R and TLRs in mast cells.
To biochemically address this hypothesis, we first investigated
A20 expression kinetics in murine bone-marrow-derived mast cells
(BMMCs) upon activation by LPS, IL-1b, IL-33, and FceRI cross-
linking. A20 transcript levels peaked 3 h after activation and
declined steadily afterwards, with IL-33 being the most potent
inducer (Figure 1A and Figure S1A). A20 protein levels increased
3–6 h after activation and remained elevated for up to 12 h
(Figure 1A and Figure S1B). In order to avoid potential biases
through effects of gene deficiencies during mast cell in vitro
development, we employed the novel KitCreERT2 transgene [21,22].
This allowed very efficient inducible expression of a fluorescent
reporter protein (Figure 1B), and excision of conditional A20 and
MyD88 alleles in BMMCs (Figure 1C) did not affect c-Kit and
FceRI levels (Figure S1C). A20-deficient mast cells activated by
LPS, IL-33, and FceRI cross-linking showed enhanced activation
of NF-kB as indicated by prolonged degradation and delayed
resynthesis of its inhibitor I-kBa, while no differences in the
activation of MAPK signaling were observed (Figure 1D–F and
Figure S1D).
Collectively, these results show that A20 is a central negative
feedback regulator of NF-kB signaling and mast cell activation in
response to TLR ligands, IL-33, and antigen/IgE complexes.
Mast Cell-Specific Ablation of A20 in Vivo Does Not
Induce Spontaneous Pathology
We observed dramatically enhanced NF-kB activation in A20-
deficient mast cells in response to various physiologically relevant
stimuli in vitro. Therefore, we generated mice lacking A20
specifically in connective tissue-type mast cells (Mcpt5Cre A20F/F)
[16,23]. In order to specifically dissect innate MyD88-dependent
from other signals, we generated mice containing mast cells
deficient for both A20 and MyD88 (Mcpt5Cre A20F/FMyD88F/F)
[24]. Most experiments were controlled with Mcpt5Cre transgenic
animals and, to a lesser extent, with nontransgenic littermates. As
we did not observe any differences between those two groups, they
are shown together as control mice.
Mcpt5Cre A20F/F mice developed normally, showing no macro-
scopic signs of disease (unpublished data). A20-deficient mast cells
homed to their natural positions in the dermis and normal
proportions were located in close proximity to blood vessels
(Figure 2A). Mast cell numbers in the ear and dorsal skin were not
significantly altered in Mcpt5Cre A20F/F compared to control mice
(Figure 2A and Figure S2A). A20 deficiency did not affect the
proportions (Figure 2B) or surface phenotype (Figure 2C) of mast
cells in the peritoneal cavity. However, absolute mast cell numbers
were significantly increased in Mcpt5Cre A20F/F mice in compar-
ison to controls, due to an overall increase in peritoneal cellularity
(Figure 2D). Furthermore, we observed enhanced frequencies of
TNF-, IL-4–, and IL-13–producing peritoneal mast cells in
Mcpt5Cre A20F/F in comparison to control mice (Figure 2E and
Figure S2B). Ablation of MyD88 in addition to A20 led to a
normalization of mast cell numbers (Figure 2D) and cytokine
production (Figure 2E and Figure S2B). Complete ablation of A20
and MyD88 was confirmed by Western blotting of peritoneal
cavity-derived mast cell (PMC) cultures (Figure S2C). To confirm
that the Mcpt5Cre transgene does not lead to A20 deletion in cell
types other than mast cells, we performed quantitative probe-
based real-time PCR on genomic DNA from cell populations
Author Summary
Mast cells mediate allergic and anaphylactic immune
reactions. They are also equipped with innate pattern
recognition, cytokine, and alarmin receptors, which induce
inflammatory responses. Correlative studies in human
patients hinted at roles for mast cells in autoimmune
and inflammatory diseases. However, studies using mast
cell-deficient mice have yielded contradictory results in
this context. In this study we determined that A20, the
negative feedback regulator, restricts inflammation down-
stream of the mast cell antigen (allergen) receptor module,
innate pattern recognition receptors, and the alarmin
receptor IL-33R. By mast cell–specific ablation of A20 we
established a mouse model for exaggerated inflammatory
but normal anaphylactic mast cell signaling. With these
mice we evaluated the impact of increased mast cell-
mediated inflammation under experimental conditions
aimed at mimicking several inflammatory human diseases.
Our results demonstrated that the lack of A20 from mast
cells exacerbated disease in mouse models for rheumatoid
arthritis and innate forms of asthma, but did not impact
disease progression in a mouse model for multiple
sclerosis. Our data provide direct evidence that enhanced
inflammatory mast cell responses can contribute to
disease pathology and do so via sensing and amplifying
local inflammatory reactions driven by ‘‘danger’’ stimuli
and/or tissue damage that leads to the release of alarmins.
A20 Limits FceRI, TLR, and IL-33R Signals
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purified from Mcpt5Cre A20F/F animals. Using this sensitive approach
we determined that less than 0.1% of A20-deficient cells are contained
among sorted leukocytes (T and B cells) and various myeloid cell
populations (Figure S2D), if any. Interestingly, analysis of secondary
lymphoid organs revealed minor splenomegaly in Mcpt5Cre A20F/F
mice in comparison to controls, which depended on signals via
MyD88 (Figure S2E).
Our results thus indicate that MyD88-dependent signals in vivo
induce a preactivated or poised state in A20-deficient mast cells
without causing spontaneous general inflammation.
A20 Deficiency Prolongs Survival and Enhances
Proliferation of Activated Mast Cells
Mcpt5Cre A20F/F mice showed elevated mast cell numbers in the
peritoneal cavity. This could be due to enhanced mast cell survival
as A20 has also been implicated in cell death responses
[13,15,16,18]. To clarify the function of A20 in mast cell survival,
we studied growth factor deprivation-induced apoptosis, which in
BMMCs is antagonized by prosurvival members of the Bcl-2
family including the NF-kB target genes Bcl-xL and A1 [25]. As
A20-deficient mast cells showed stronger NF-kB activation in
Figure 1. A20 is a specific negative feedback regulator of NF-kB activation in mast cells. (A) Wild-type BMMCs were stimulated with
10 mg/mL LPS or 10 ng/mL IL-33 for the indicated time intervals. To induce FceRI cross-linking, BMMCs were loaded overnight with 1 mg/mL anti-DNP
IgE and subsequently stimulated with 10 ng/mL DNP–HSA. A20 mRNA and protein levels were determined by quantitative RT-PCR and Western
blotting, respectively. Changes in mRNA levels normalized to PBGD (black bars) and protein levels normalized to GAPDH (white bars) relative to time-
point 0 h are shown. Data are means + SD from three independent experiments. (B) Schematic representation of the KitCreERT2 knock-in allele. Black
and grey histograms show representative YFP expression in BMMCs derived from KitCreERT2/+R26-StopFYFP and control animals, respectively, treated
for 7 d with 1 mM 4-hydroxytamoxifen. (C) Western blot of whole BMMC lysates of the indicated genotypes unstimulated or activated for 3 h with
10 mg/mL LPS or 10 ng/mL IL-33. Data are representative of three independent experiments. (D–F) Western blots of whole BMMC lysates stimulated
for the indicated time intervals with 10 mg/mL LPS (D), 10 ng/mL IL-33 (E), or loaded for 2 h with 1 mg/mL anti-DNP IgE and subsequently stimulated
with 10 ng/mL DNP–HSA (F). Data are representative of at least two independent experiments.
doi:10.1371/journal.pbio.1001762.g001
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response to stimulation, we reasoned that loss of A20 could protect
activated mast cells from IL-3 and SCF withdrawal-induced cell
death.
A20 deficiency per se did not affect growth factor deprivation-
induced cell death, and stimulation with monomeric IgE generally
enhanced mast cell survival by an A20-independent pathway
(Figure 3A). However, treatment with LPS remarkably increased
survival only of mast cells lacking A20. IL-33 had a small effect on
wild-type mast cells but profoundly inhibited cell death in the
absence of A20 (Figure 3A). Stimulation with LPS or IL-33
enhanced the transcription of all tested pro-survival members of
the Bcl-2 family in A20-deficient cells in comparison to controls,
with A1 being most prominently affected (Figure 3B). Enhanced
expression of Bcl-xL protein was confirmed by Western blotting
(Figure 3C). All these processes were strictly MyD88-dependent
(Figure 3A–C). We thus conclude that A20 deficiency increases the
up-regulation of pro-survival Bcl-2 family members upon innate
activation. This is one potential mechanism of how loss of A20 can
lead to a dramatically enhanced protection against apoptosis. In
addition, cell cycle analysis showed an increase in proliferative
activity of LPS and IL-33–stimulated A20-deficient mast cells,
which depended on signals transmitted via MyD88 (Figure 3D).
Collectively, these results indicate that naturally occurring
MyD88-transmitted stimuli can promote the survival and prolif-
eration of A20-deficient mast cells.
Loss of A20 in Mast Cells Enhances Allergic Airway
Inflammation
Next we investigated the consequences of mast cell-specific A20
deficiency in allergic, inflammatory, and autoimmune conditions.
Asthma is a chronic inflammatory disease of the airways
characterized by increased presence of eosinophils and production
of Th2 cytokines, such as IL-13, that causes bronchial hyperre-
activity and goblet cell metaplasia. The classical mouse asthma
model, which is induced by injection of ovalbumin (OVA) together
with alum adjuvant, is mast cell independent in KitW/Wv and
KitW-sh/W-sh mice. In contrast, a clear role for mast cells has been
demonstrated in models of asthma that employ OVA as an
Figure 2. In vivo homeostasis of A20-deficient mast cells. (A) Representative immunofluorescence images of whole-mount ear explants: green,
avidin-FITC; red, anti-laminin; scale bar, 100 mm. Scatter plot shows proportions of mast cells (CD45+FceRI+c-Kit+) in ear skin digests as identified by
flow cytometric analysis. Bars indicate means from at least eight mice per genotype (Control, 7 Mcpt5Cre, 3 Cre2 littermates). (B) Dot plots showing
proportions of ex vivo isolated peritoneal mast cells (FceRI+c-Kithi). Numbers represent means 6 SD from at least 20 mice per genotype (Control, 15
Mcpt5Cre, 5 Cre2 littermates). (C) Median fluorescent intensities (MFIs) of various cell surface markers expressed on A20-deficient and control ex vivo
isolated peritoneal mast cells. Data are means + SD from at least four mice per genotype (Control, 4 Mcpt5Cre, 1 Cre2 littermate). (D) Scatter plots
show absolute numbers of peritoneal mast cells (FceRI+c-Kithi) and total peritoneal cells. Bars indicate means from at least 10 mice per genotype
(Control, 8 Mcpt5Cre, 5 Cre2 littermates). (E) Scatter plots show proportions of cytokine positive peritoneal mast cells (c-Kit+) as identified by
intracellular flow cytometric analysis. Bars indicate means from at least eight mice per genotype (Control, 9 Mcpt5Cre, 2 Cre2 littermates). *p,0.05,
**p,0.01, ***p,0.001 (one-way ANOVA).
doi:10.1371/journal.pbio.1001762.g002
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allergen in the absence of alum [26,27]. To address the effect of
mast cell-specific A20 deficiency in mouse asthma models, we
immunized mice with OVA either in the presence or absence of
alum, and challenged mice 10 d later with 1% OVA aerosols. In
the OVA/alum model, loss of A20 in mast cells did not affect the
number of bronchoalveolar lavage (BAL) fluid eosinophils, B and
T cells, and the production of IL-13 by mediastinal lymph node
(MLN) mononuclear cells or serum levels of OVA-specific IgE
(Figure 4A). In contrast, when mice were actively sensitized to
OVA in the absence of alum, all these parameters were signifi-
cantly elevated in Mcpt5Cre A20F/F compared to control mice
(Figure 4B).
House dust mite (HDM) allergens are the most common triggers of
allergic asthma and robustly induce IgE-dependent lung inflammation
with many features of human asthma in mice [28–30]. To our
knowledge, the role of mast cells has not yet been genetically
addressed in this arguably more relevant model. Thus we measured
the responses of Mcpt5Cre A20F/F and control mice to active
sensitization induced by administration of HDM extracts via the
nasal route followed by five HDM challenges 7 d later. Mast cell-
specific ablation of A20 caused increased levels of BAL fluid
eosinophils and B cells, and HDM-specific serum IgE (Figure 5A).
Dendritic cells (DCs) induce and maintain Th2 immunity to inhaled
allergens such as HDM and OVA [31] and are necessary and
sufficient for the development of asthma [29]. Suto et al. showed
that mast cells control the activation of DCs via the release of TNF
[32]. We therefore evaluated whether A20 deficiency in mast cells
affects DC responses to HDM exposure. Indeed HDM treatment
Figure 3. A20 deficiency enhances survival and proliferation of LPS- and IL-33-activated mast cells. (A) Survival kinetics of IL-3 and SCF-
deprived BMMCs cultured in simple medium or supplemented with 5 mg/mL anti-DNP IgE, 10 mg/mL LPS, or 10 ng/mL IL-33. Cell death was
quantified at the indicated time points after propidium iodide staining and flow cytometric analysis. Data are means 6 SD from at least three
independent experiments. (B) RNA was purified from BMMCs treated for 24 h as described in (A) and Bcl-2, Bcl-xL, and A1 mRNA levels were
determined by quantitative RT-PCR. Relative changes in transcript levels to unstimulated (Bcl-xL and Bcl-2) or IgE-stimulated (A1) wild-type BMMCs
were calculated after normalization for PBGD. Data are means + SD from three independent experiments. (C) Western blot of whole BMMC lysates
treated for 24 h as described in (A). Numbers denote changes in Bcl-xL protein levels relative to unstimulated wild-type BMMCs. Data are
representative of and numbers are means from three independent experiments. (D) Cell cycle profile analysis by propidium iodide staining of BMMCs
cultured for 4 d in full medium alone or supplemented with 10 mg/mL LPS or 10 ng/mL IL-33. Percentages of live cells in G2/M phase are shown and
are means + SD from two independent experiments with two independent mast cell preparations. **p,0.01, ***p,0.001 (one-way ANOVA).
doi:10.1371/journal.pbio.1001762.g003
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led to enhanced recruitment of DCs to the lung and MLNs in
Mcpt5Cre A20F/F mice in comparison to controls. In addition, these
DCs had taken up significantly more fluorescent antigen (Figure 5B).
These findings are in line with our observations that A20-deficient
mast cells produce more TNF upon activation. As mast cells have
been shown to control vascular permeability [9], we wondered
whether the increase in airway inflammation in Mcpt5Cre A20F/F
mice could also be linked to enhanced vascular leakage. Therefore,
we injected fluorescently labeled 500 nm microspheres intrave-
nously 1 h after HDM allergen challenge and measured their
extravasation 5 min later. In line with our hypothesis, Mcpt5Cre
A20F/Fmice displayed a strong increase in vascular leakage compared
to control mice (Figure 5C). We and others have previously reported
that the HDM-driven model of asthma depends on the activity of
IL-33 and is driven by antigen-presenting DCs [28,33]. In control
mice, three intranasal administrations of IL-33 induced an increase
in the total cell and DC influx into the lungs, which was enhanced
by ablation of A20 specifically in mast cells (Figure 5D). In addition,
there was a trend towards increased numbers of eosinophils,
neutrophils, and monocytes in the lungs of Mcpt5Cre A20F/F mice
(Figure S3). Hence, the increased sensitivity of A20-deficient mast
cells towards IL-33 could contribute to the enhanced allergic
responses observed in Mcpt5Cre A20F/F mice. This notion is
supported by the fact that Mcpt5Cre A20F/F mice showed signi-
ficantly elevated numbers of granulocytes, lymphocytes, and DCs in
the BAL fluid after OVA aerosol challenge, when the OVA
sensitization occurred in the presence of IL-33 (Figure 5E). We
employed the above-described PCR assay (see Figure S2D) to
confirm that under inflammatory conditions, Mcpt5Cre-mediated
recombination of loxP-flanked A20 alleles is still restricted to mast
cells. We did not detect recombination of conditional alleles in the
following cellular subsets purified and pooled from eight HDM-
challenged Mcpt5Cre A20F/F mice, which exceeded the background
signal detected in the corresponding population purified and pooled
from eight A20F/F mice: Lung B cells, DCs, monocytes and
neutrophils, BAL fluid eosinophils, and peritoneal cavity macro-
phages (unpublished data).
In summary, we show that enhanced connective tissue-type
mast cell responses to allergens and the alarmin IL-33 significantly
aggravate allergic lung inflammation.
Figure 4. Enhanced OVA-induced airway inflammation in Mcpt5Cre A20F/F mice in the absence of alum. (A) Scatter plots show absolute
BAL fluid cell numbers of Eos (eosinophils, SSChi, Siglec-F+, Gr-1int, CD11c2), B cells (FSC/SSClo, CD19+, MHCII+), and T cells (FSC/SSClo, CD3+, MHCII2),
as identified by flow cytometric analysis. IL-13 cytokine production by MLN cells and OVA-specific IgE levels were measured by ELISA. Bars indicate
means; data are integrated from two experiments and are representative of three independent experiments with four to eight mice per group
(Control, 8 ‘‘PBS/alum’’ and 11 ‘‘OVA/alum’’ Cre2 littermates). (B) Scatter plots show absolute BAL fluid cell numbers of Eos (eosinophils, SSChi, Siglec-
F+, Gr-1int, CD11c2), B cells (FSC/SSClo, CD19+, MHCII+), and T cells (FSC/SSClo, CD3+, MHCII2), as identified by flow cytometric analysis. IL-13 cytokine
production by MLN cells and OVA-specific IgE levels were measured by ELISA. Bars indicate means, and data are integrated from two independent
experiments with two to eight mice per group (Control, 5 ‘‘PBS’’ and 8 ‘‘OVA’’ Cre2 littermates). *p,0.05, **p,0.01, ***p,0.001 (Mann-Whitney test).
doi:10.1371/journal.pbio.1001762.g004
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Figure 5. Enhanced inflammation in Mcpt5Cre A20F/F mice in the HDM, IL-33, and OVA + IL-33 asthma models. (A) Scatter plots show
absolute BAL fluid cell numbers of Eos (eosinophils, SSChi, Siglec-F+, Gr-1int, CD11c2), B cells (FSC/SSClo, CD19+, MHCII+), and T cells (FSC/SSClo, CD3+,
MHCII2), as identified by flow cytometric analysis. Cytokine production by MLN cells and HDM-specific IgE levels were measured by ELISA. Bars
indicate means, and data are representative of three independent experiments with four to six mice per group (Control, 5 ‘‘PBS’’ and 6 ‘‘HDM’’ Cre2
littermates). (B) Mice received 100 mg HDM extract and 10 mg OVA-AF647 intratracheally and were analyzed 18 h later. Scatter plots show absolute
numbers of DCs (DCs, CD11c+, MHCIIhi, nonautofluorescent) and antigen positive DCs (AF647+) in the lung and MLNs as identified by flow cytometric
A20 Limits FceRI, TLR, and IL-33R Signals
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A20-Deficient Mast Cells Aggravate Collagen-Induced
Arthritis (CIA) But Not Experimental Autoimmune
Encephalomyelitis (EAE)
We showed that A20-deficient mast cells worsen inflammation
during allergic airway responses. Mast cells were also implicated in
autoimmune diseases such as multiple sclerosis and arthritis [7,34].
However, the absence of mast cells had contradicting effects
during the induction of model diseases in the mouse [5,8,35–37].
Hence we revisited this important issue in our novel gain-of-
function model.
We induced EAE through standard protocols in control and
Mcpt5Cre A20F/F mice. Monitoring of disease incidence as well as
severity (clinical score) did not yield any differences between both
groups (Figure 6A). Thus, A20-deficient connective tissue-type
mast cells do not influence T-cell-driven EAE.
Both genetic association studies and experimental approaches in
mouse models suggested that mast cells and A20 play a
pathological role in rheumatoid arthritis [12,18,34]. Interestingly,
many studies showed a pathological role of IL-33 in CIA [38,39].
In line with our previous results, suggesting an important role for
A20 in controlling IL-33R signaling, Mcpt5Cre A20F/F mice
exhibited an earlier onset of disease after immunization compared
to control mice (Figure 6B). Also disease incidence and severity, as
assessed by clinical score and paw swelling (Figure 6B and Figure
S4A), were significantly exacerbated by A20 deficiency in mast
cells. Evaluation of pathology by histology corresponded well with
the clinical scores (Figure S4B). Systemically, we detected slightly
elevated levels of TNF (Figure S4C) and an expansion of splenic B
and T cell numbers inMcpt5Cre A20F/F mice, pointing to increased
inflammation (Figure S4D). Concomitant ablation of MyD88
reversed the effects of mast cell-specific A20 loss during arthritis
induction to a large extent (Figure 6B and Figure S4A–D),
indicating essential roles for IL-33, TLR ligands, and/or IL-1b.
Taken together, our data show that A20-deficient connective
tissue-type mast cells did not affect EAE, but increased the severity
of arthritis-associated inflammation.
A20 Deficiency Does Not Affect Immediate But
Exacerbates Late Phase Anaphylactic Mast Cell
Responses
In order to dissect how A20-deficient mast cells exacerbate
pathological immune responses in vivo, we first addressed IgE/
FceRI-induced mast cell activation that prominently provokes
degranulation, in addition to pro-inflammatory NF-kB activation
[20]. To explore consequences of A20 deficiency in connective
tissue-type mast cells on anaphylactic responses in vivo, we
performed FceRI-mediated immediate phase passive cutaneous
anaphylaxis (PCA) and passive systemic anaphylaxis (PSA)
experiments, which depend on mast cell degranulation [8,20].
The vascular leakage in IgE primed ears in immediate phase PCA
reactions (Figure 7A), as well as changes in core body and skin
temperature during PSA reactions (Figure 7B and Figure S5A), did
not differ significantly between control and Mcpt5Cre A20F/F mice.
However, we observed a minor trend towards stronger responses
in Mcpt5Cre A20F/F mice. Therefore, we embarked on extensive in
vitro degranulation analyses using both BMMCs and PMCs. IgE/
FceRI engagement by antigen induced the same extent of
degranulation in A20-deficient BMMCs (Figure 7C and D) and
PMCs (Figure 7E) in comparison to controls. Prolonged priming
with IgE and stimulation with IL-33 or TLR ligands alone or in
addition to antigenic challenge did not reveal a role for A20 during
degranulation and histamine release (Figure S5B–F). Therefore,
the minor increase in in vivo responses might be due to the slightly
elevated mast cell numbers in Mcpt5Cre A20F/F in comparison to
control mice. Collectively, our results show that A20 does not
regulate degranulation and hence anaphylactic responses.
analysis. Bars indicate means from six to seven mice per group (Control, 6 ‘‘PBS’’ and 7 ‘‘HDM’’ Cre2 littermates). (C) Representative confocal images of
trachea whole mounts of HDM sensitized and challenged mice after i.v. injection of FITC+ 500 nm microbeads: green, FITC+ microbeads; red, anti-
CD31. (D) Mice were administered 100 ng IL-33 i.n. on 3 consecutive days. Scatter plots show absolute lung cell numbers and DCs (CD11c+, MHCIIhi,
nonautofluorescent) as identified by flow cytometric analysis. Bars indicate means from three to six mice per group (Control, 3 ‘‘PBS’’ and 5 ‘‘IL-33’’
Cre2 littermates). (E) Scatter plots show absolute BAL fluid cell numbers, granulocytes (SSCintRhi, Ly6C+, Ly6GintRhi, CD11b+, CD11c2), lymphocytes
(FSC/SSClo, CD3+, or CD19+), and DCs (CD11c+, MHCIIhi, nonautofluorescent) as identified by flow cytometric analysis. Bars indicate means, and data
are integrated from two independent experiments with two to six mice per group (Control, 5 ‘‘OVA’’ and 10 ‘‘OVA + IL-33’’ Cre2 littermates). *p,0.05,
**p,0.01 (Mann-Whitney test).
doi:10.1371/journal.pbio.1001762.g005
Figure 6. Enhanced joint but normal nervous system inflam-
mation in Mcpt5Cre A20F/F mice. (A) EAE disease incidence was
assessed and severity scored every day based on clinical symptoms.
Data are mean scores of sick animals 6 SEM (for visual clarity instead of
SD) from at least 11 mice per genotype (Control, 12 Mcpt5Cre mice). (B)
CIA disease incidence was assessed and severity scored every second
day based on clinical symptoms. Data are mean scores of sick animals6
SEM (for visual clarity instead of SD) from at least 10 mice per genotype
(Control, 16 Mcpt5Cre mice). **p,0.01 (Log-rank (Mantel-Cox) test).
doi:10.1371/journal.pbio.1001762.g006
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We next performed late phase PCA responses, which are
thought to be promoted by NF-kB activation in mast cells [20]. In
this model, Mcpt5Cre A20F/F mice showed significantly enhanced
ear swelling compared to controls (Figure 7F and Figure S5G).
Our data thus demonstrate that A20 does not regulate IgE/
FceRI-induced signals leading to degranulation and immediate
anaphylactic events but rather late phase reactions.
A20 Deficiency Causes Mast Cell Hyperactivity Leading to
Increased Cytokine Production, Activation Marker
Expression, and Alarmin Production in Fibroblasts
As A20 deficiency did not affect mast cell degranulation, we
examined if enhanced pro-inflammatory reactions could account
for the exacerbated responses observed in Mcpt5Cre A20F/F mice.
Hence, we dissected the activation state of A20-deficient mast cells
in vitro. Stimulation with LPS, IL-33, and IL-1b induced drama-
tically augmented transcription and secretion of pro-inflammatory
cytokines such as TNF, IL-6, and IL-13 from A20-deficient in
comparison to control mast cells (Figure 8A and Figure S6A–C).
PMA/Iono-induced release of IL-2 was unchanged (Figure S6D).
A trend towards an increase in IL-1b secretion was also observed
(Figure S6E). In addition, the enhanced responses of A20-deficient
mast cells to LPS and IL-33 were demonstrated by increased up-
regulation of the activation markers OX40L, CD30L, CD25, Fas,
and 4-1BB (Figure 8B). Ablation of MyD88 completely abolished
the enhanced production of cytokines and rescued the hyperactive
phenotype caused by A20 deficiency (Figure 8A and B and Figure
S6B,C, and E). A20-deficient mast cells also produced more pro-
inflammatory cytokines than wild-type mast cells in response to
priming with IgE and to FceRI cross-linking (Figure 8C and
Figure S6F and G). A recent study proposed that during arthritis
IL-33 released by synovial fibroblasts activates mast cells, which in
turn, by their secretion of pro-inflammatory cytokines, could
enhance IL-33 expression in the former, leading to a paracrine
feed-forward loop [38]. Supernatants of IL-33–stimulated A20-
deficient hyperactive mast cells induced significantly more IL-33
production in synovial fibroblasts than supernatants of IL-33–
stimulated control mast cells (Figure 8D). This indicates that the
lack of A20 in mast cells could amplify local IL-33–mediated feed-
forward loops to exacerbate inflammation.
Collectively, our results demonstrate that in mast cells A20 is a
selective negative feedback regulator of NF-kB–mediated inflammatory
Figure 7. Normal degranulation and immediate but exacerbated late phase anaphylactic responses in the absence of A20. (A)
Representative images of immediate phase PCA reactions (PBS, left ear; anti-DNP IgE, right ear). Evans blue extravasation was quantified by extraction
and photometric analysis. Data show differences in dye extravasation between IgE and PBS injected ears, and bars are medians from five mice per
genotype (Control, 5 Mcpt5Cre mice). (B) Data show changes in rectal temperature over time during PSA reactions and are means 6 SEM (for visual
clarity instead of SD) from at least 22 mice per genotype (Control, 7 Mcpt5Cre and 16 Cre2 littermates). (C) BMMCs were loaded for 2 h with 1 mg/mL
anti-DNP IgE and subsequently stimulated for 20 min with 10 ng/mL DNP-HSA, stained with Annexin V-Cy3, and analyzed by flow cytometry.
Representative histograms including MFIs and fold increase in Annexin V binding are shown comparing IgE loaded with degranulated BMMCs. Data
are means + SD from at least five independent mast cell preparations. (D and E) BMMCs (D) or PMCs (E) were loaded as in (C) and subsequently
stimulated for 30 min with the indicated concentrations of DNP–HSA or 500 ng/mL A23187. Degranulation was determined by measuring the activity
of b-hexosaminidase in supernatants and cell lysates. Data are means + SD from seven (D) or three (E) independent mast cell preparations. (F) Data
show increase in ear thickness during late phase PCA reactions and are means 6 SEM (for visual clarity instead of SD) from at least seven mice per
genotype (Control, 8 Mcpt5Cre and 13 Cre2 littermates). *p,0.05, **p,0.01 (unpaired t test).
doi:10.1371/journal.pbio.1001762.g007
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signaling events but not of anaphylactic IgE:FceRI–induced
degranulation. Loss of A20 dramatically enhances their pro-
inflammatory properties and causes profound mast cell hyperacti-
vation. A20-deficient hyperactive connective tissue-type mast cells
exacerbate lung as well as late phase skin inflammation and CIA,
pointing to an important contribution of mast cells in these diseases.
Discussion
Experiments in mast cell-deficient mice that carry hypomorphic
c-Kit mutations have not only positioned mast cells as central
mediators of allergic and anaphylactic responses but also in
inflammatory and autoimmune diseases. However, recent exper-
iments employing novel Kit-independent mast cell-deficient mice
challenged this notion, which urged for a reassessment of their
exact role in immunological and inflammatory reactions [5]. To
study their contribution to particular immune reactions, one can
assay the presence of mast cells and their activation status, the
effects of mast cell deficiency, or the effects of mast cell
hyperactivity, akin to the modified Koch’s postulates for immu-
nology [40]. Hence, we established a novel gain-of-function in vivo
approach by ablating the NF-kB negative feedback regulator A20
specifically in connective tissue-type mast cells. This led to
hyperactive mast cells with overshooting inflammatory responses
Figure 8. A20 is a key negative regulator of mast cell activation. (A) TNF, IL-6, and IL-13 secretion of BMMCs stimulated for 6 h with 10 mg/mL
LPS or 10 ng/mL IL-33 were measured by ELISA. Data are means + SD from three independent experiments. (B) Expression levels of cell surface
activation markers on BMMCs stimulated for 3 d with 10 mg/mL LPS or 10 ng/mL IL-33. Histograms are representative of three independent
experiments. (C) TNF and IL-6 secretion of BMMCs loaded for 2 h with 1 mg/mL anti-DNP IgE and subsequently stimulated for 6 h with 10 ng/mL
DNP–HSA were measured by ELISA. Data are means + SD from at least four independent experiments. (D) Synovial fibroblasts were stimulated with
filtered supernatants (SNs) from A20-deficient and control BMMCs, which were activated overnight with 10 ng/mL IL-33. IL-33 mRNA levels in synovial
fibroblasts (8 h stimulation with SNs or 10 ng/mL IL-1b and TNF) were determined by quantitative RT-PCR, normalized to PGBD, and changes relative
to unstimulated fibroblasts are shown. IL-33 protein levels (24 h stimulation with SNs) were analyzed by Western blotting. Data are means + SD from
at least three (RT-PCR) or representative of two (Western blot) independent experiments using SNs from two independent mast cell preparations.
*p,0.05, **p,0.01, ***p,0.001 (one-way repeated measures ANOVA).
doi:10.1371/journal.pbio.1001762.g008
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to common disease-causing stimuli. We cannot completely exclude
the possibility that loss of A20 has consequences on mast cell
differentiation and/or functions in addition to amplifying inflam-
matory signaling and that this might influence the outcome of our
experiments. However, A20’s function as a very potent activation-
induced negative feedback regulator in mast cells indicates that
our interpretation of its role in the context of inflammatory
diseases is warranted. This view is strongly supported by the fact
that many of the phenotypes we observed can be neutralized by
co-ablation of MyD88.
Our results demonstrate that A20 does not regulate instant
degranulation, which is triggered by antigen binding to the
IgE:FceRI module and is critical for immediate cutaneous and
systemic anaphylactic reactions. In contrast, A20 serves as a
feedback inhibitor of FceRI-initiated NF-kB activity and in its
absence the secretion of pro-inflammatory cytokines, and thereby
late phase PCA reactions are strongly amplified. Therefore, it
should be possible to modulate A20 function without provoking
anaphylactic reactions. Although pharmacological augmentation
of A20 function is mainly discussed in the context of treating
inflammatory and autoimmune diseases [17], its inhibition might
be beneficial to enhance immunogenicity of vaccines and the
management of viral infections [14,41].
In addition, also in mast cells A20 limits pro-inflammatory gene
expression upon stimulation with TLR ligands and cytokines.
Furthermore, inflammation can be triggered by alarmins released
by dying cells, such as the recently identified IL-33 [42]. Mast cells
can sense IL-33 by virtue of their characteristic high constitutive
IL-33R a-chain expression [43]. We discovered that A20 acts as a
key negative feedback inhibitor of IL-33–induced MyD88-
dependent NF-kB but not MAPK activation in mast cells. A20
deficiency leads to dramatically enhanced cytokine production,
activation marker expression, resistance to apoptosis, and
increased proliferation upon stimulation with IL-33. As IL-33
can also be sensed by dendritic and myeloid cells [44], IL-33–
induced activation in the steady state could contribute to the
spontaneous MyD88-dependent pathologies observed in mice that
lack A20 specifically in these cell types [12,14]. Furthermore, IL-
33 triggers activation of group 2 innate lymphoid cells, Th2 cells,
NKT cells, B cells, NK cells, eosinophils, and basophils [44]. We
therefore propose that A20’s role in limiting IL-33–mediated NF-
kB activation is of general importance in the immune system.
Loss of A20 in connective tissue-type mast cells in vivo did not
cause dramatic spontaneous inflammation. However, A20-defi-
cient peritoneal mast cells displayed a pre-activated or poised state,
which depended entirely on the presence of MyD88. This indi-
cates that mast cells, similar to other innate leukocytes [12,14],
constantly receive tonic signals that are controlled by A20, via one
or more MyD88-dependent receptors, such as TLR, IL-1R, IL-
18R, or IL-33R. The fact that A20-deficient connective tissue-type
mast cells, unlike macrophages or DCs lacking A20 [12–14], do
not cause pronounced spontaneous inflammation suggests that
these cells are intrinsically less potent inducers of inflammatory
reactions and/or have developed additional control mechanisms.
A20 is a susceptibility gene locus for rheumatoid arthritis
[17,18], and mast cells are implicated in the pathogenesis of this
disease [34]. Several recent studies pointed to a crucial role of IL-
33 during arthritis [45], which could promote joint inflammation,
at least in part, by activating mast cells [38]. This notion is in line
with our observation that hyperactive A20-deficient mast cells
caused earlier onset as well as exacerbation of CIA symptoms. In
contrast, A20-deficient connective tissue-type mast cells did not
worsen symptoms of MOG peptide-induced EAE, possibly
because initiation of this disease is IL-33 independent [33]. Our
results do not strictly exclude a role of mast cells in this model, as it
remains possible that general mast cell hyperactivation might have
different or more pronounced effects than those elicited by the loss
of A20 in connective tissue-type mast cells alone. Nevertheless, our
results illustrate that profound hyperactivation of the inflammatory
properties of connective tissue-type mast cells does not affect the
outcome of EAE induction.
Arthritis can develop in absence of an adaptive immune system,
driven solely by A20-deficient innate immune cells [12]. We
propose that in the context of autoimmune arthritis, A20-deficient
mast cells exacerbate local inflammation in the joint. Tissue damage
or physical stress during the early stages of arthritis development
cause local release of endogenous TLR ligands or alarmins such as
IL-33. Pro-inflammatory cytokine secretion by A20-deficient mast
cells results in a locally restricted auto-amplification loop by
enhancing IL-33 expression in synovial fibroblasts leading to
stronger mast cell activation in a paracrine fashion. This scenario
is supported by our data that MyD88 deficiency in mast cells
counteracts the early onset and disease severity caused by ablation
of A20.
Amplification of detrimental IL-33–mediated feed-forward
loops by loss of A20 function might not be restricted to initial
stages in arthritis but could also play an important role in other
inflammatory conditions including psoriasis, systemic sclerosis,
inflammatory bowel disease, and asthma, which have an IL-33
component and are associated with A20 or A20 binding partner
(TNIP1) gene locus polymorphisms [17–19,44,45]. Furthermore,
IL-33 is increased in human asthmatics, and recent genome-wide
association studies have identified the genes encoding for IL-33
and its receptor as susceptibility loci for asthma [44]. Also in our
asthma models, IL-33 is released by stromal cells, such as epithelial
and smooth muscle cells, after HDM provocation [28,46]. Mast
cell numbers increase during allergic airway inflammation and
then localize within the smooth muscle, where they enhance
bronchial hyperreactivity [47]. This localization hence enables
mast cells to easily sense IL-33, and A20 deficiency amplifies their
ensuing responses, exacerbating immune cell activation and lung
inflammation. Fittingly, IL-33 could also be used as an adjuvant to
induce Th2 immunity, which was enhanced by mast cells in
Mcpt5Cre A20F/F mice, possibly by promoting an initial pro Th2
innate response to IL-33 as indicated by the increased DC
numbers in the airways. The stronger general immune activation
elicited by alum probably overrides these mast cell-dependent
effects in the OVA/alum model [26,27]. Since the HDM model is
much closer to the human situation, our data clearly indicate that
inflammatory functions of connective tissue-type mast cells can
contribute to allergic inflammatory airway diseases. The role of
mast cells in airway hyperreactivity has been studied predomi-
nantly in mast cell-deficient c-Kit mutant mouse strains, which did
not allow dissecting the role of individual mast cell subsets [26,27].
Our model, with selective hyperinflammatory properties of
connective tissue-type mast cells, points to an important role for
this subset in controlling asthma. However, our findings do
exclude a role for mucosal mast cells in this disease.
In conclusion, our data demonstrate that loss of A20 specifically
amplifies NF-kB controlled gene expression programs in connec-
tive tissue-type mast cells during inflammatory, allergic, and
autoimmune conditions. We demonstrate that, in addition to its
known function downstream of TLRs and the IL-1R, A20 also
plays a critical role as a negative feedback inhibitor of IL-33R–
and FceRI-initiated pro-inflammatory signaling pathways. It does
not, however, regulate IgE-dependent anaphylactic responses. As
a result, the magnitude of inflammatory responses can be con-
trolled through pharmacological intervention modulating A20
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levels or activity without affecting anaphylactic reactions. Our
study demonstrates, to our knowledge for the first time, the
consequences of inflammatory mast cell hyperreactivity, identify-
ing mast cells as therapeutic targets in airway inflammation and
autoimmune arthritis. Our data also suggest that alterations in
mast cell function could contribute to the pathologies linked to
genetic polymorphisms in the A20 gene locus or some of its bind-
ing partners (for example, TNIP1) that are associated with auto-
immune, such as rheumatoid arthritis, or allergic diseases [17–19].
Materials and Methods
Genetically Modified Mice
Mcpt5Cre [23], A20F [16], MyD88F [24], R26-StopFYFP [48], and
KitCreERT2 mice [21,22] were kept on a C57BL/6 genetic back-
ground. All animal procedures were approved by the Regierung of
Oberbayern and the Animal Ethics Committee of the University
of Ghent.
Passive Cutaneous and Systemic Anaphylaxis
For immediate phase PCA reactions, mice were passively
sensitized by intradermal injection of 100 ng anti-DNP IgE (SPE-7
supernatant) into one ear and PBS into the contralateral ear. After
24 h, mice were challenged by intravenous (i.v.) injection of
200 mg DNP-HSA in 0.5% Evans blue (both Sigma-Aldrich).
Extravasation was quantified by dimethylformamid extraction and
photometric quantification.
For late phase PCA reactions, mice were sensitized by i.v.
injection of 20 mg anti-DNP IgE (SPE-7 supernatant) and 24 h
later challenged by epicutaneous application of 20 mL 0.2%
DNFB (Sigma-Aldrich) in acetone/olive oil (4:1) to one ear and
vehicle to the contralateral ear followed by measuring ear
thickness over time using a thickness gauge (Mitutoyo).
For PSA reactions, mice were sensitized by intraperitoneal (i.p.)
injection of 10 mg anti-DNP IgE (SPE-7 supernatant) and 24 h
later challenged by i.p. injection of 100 mg DNP-HSA. Systemic
anaphylactic response was monitored by measuring changes in
body temperature using a rectal thermometer (Bioseb) or changes
of dorsal skin temperature using a thermography camera (Jenoptik).
Asthma Models
OVA-specific allergic airway inflammation was induced in 6–
10-wk-old mice, either by immunization with i.p. injections of
10 mg OVA on 7 alternated days or by an i.p. injection of OVA/
Alum (10 mg OVA adsorbed to 1 mg aluminum hydroxide;
Sigma-Aldrich) at day 0 and day 7. In both models, mice were
challenged 10 d after the last i.p. OVA injection with OVA
aerosols delivered from a jet nebulizer delivering 1% OVA in PBS
for 30 min/day for 3 consecutive days. Twenty-four hours after
the last challenge, BAL fluid, blood, and the MLNs were collected.
IL-13 was measured in the supernatant of 106 MLN cells
restimulated with 15 mg/mL OVA for 4 d.
To induce HDM-specific allergic airway inflammation, mice
were sensitized intranasally (i.n.) with 1 mg HDM extracts (Greer
Laboratories) on day 0 under isoflurane sedation and were
subsequently challenged with 10 mg HDM i.n. on days 7–11. On
day 15, allergic airway inflammation was characterized as
described above. To assay DC responses, mice received 100 mg
HDM extracts (Greer Laboratories) and 10 mg OVA-AF647
(Invitrogen) intratracheally under isoflurane sedation and were
analyzed 18 h later.
To address the innate immune response to IL-33, mice were
treated on 3 consecutive days with 100 ng IL-33 i.n., and lungs
were harvested on day 4.
To provoke IL-33–induced airway inflammation, mice were
sensitized with 25 ng IL-33 (BioLegend) and 10 mg OVA and
boosted with 10 mg OVA day 7. OVA aerosols challenges were
given from day 17 to 19, and at day 20 airway inflammation was
assessed as described above.
EAE
Mice were immunized subcutaneously at two sites with 200 mg
MOG35–55 emulsified in Freund’s adjuvant (Sigma-Aldrich)
supplemented with 5 mg/mL Mycobacterium tuberculosis (strain
H37Ra, Difco). On the day of and 2 d after immunization,
400 ng pertussis toxin (List Biological Laboratories) was admin-
istered i.p. EAE severity was assessed every day based on a clinical
scoring system [49]: 0, normal; 0.5, partial limp tail; 1, complete
paralysis of the tail; 2, loss in coordinated movement, hind limb
weakness; 2.5, one hind limb paralyzed; 3, both hind limbs
paralyzed; 4, forelimbs paralyzed; and 5, moribund or dead.
CIA
Male mice were immunized intradermally at two sites at the
base of the tail with 200 mg chicken type II collagen in Freund’s
Adjuvant containing 1 mg/mL Mycobacterium tuberculosis (Sigma-
Aldrich) essentially as described [50]. Arthritis severity was
assessed every second day based on a clinical scoring system: 0,
normal; 1, slight swelling and/or erythema; 2, pronounced
edematous swelling; and 3, ankylosis. Each limb was graded,
giving a maximum score of 12. Paw thickness was measured every
second day using a thickness gauge (Mitutoyo). For histology hind
paws were fixed in 4% PFA, decalcified in 10% buffered EDTA,
embedded in paraffin, sectioned, and stained with hematoxylin
and eosin.
Flow Cytometry
Nonspecific binding of antibodies to isolated single cells was
minimized by Fc-block (CD16/32, 93, eBioscience; 2.4G2, BD),
and cells were stained with monoclonal antibodies against 4-1BB
(17B5), B220 (RA3-6B2), CD3e (145-2C11) CD4 (RM4-5), CD8
(53-6.7), CD11b (M1/70), CD11c (N418), CD19 (1D3), CD25
(PC61.5), CD30L (RM153), CD44 (IM7), CD45.2 (104), CD62L
(MEL-14), CD80 (16-10A1), CD86 (GL1), c-Kit (2B8), FceRI
(MAR-1), Gr-1 (RB6-8C5), Ly6C (HK1.4), MHC Class I (AF6-
88.5.5.3), MHC Class II (M5/114.15.2), OX40L (RM134L),
TCRb (H57-597) (all eBioscience), Fas (Jo2), Ly6G (1A8), Siglec-F
(E50-2440) (all BD), and ST2 (DJ8, MD Bioproducts). Biotinylated
antibodies were detected with fluorophore-conjugated streptavidin
(eBioscience).
Cytokine secretion of peritoneal cells was blocked for 4 h with
monensin (eBioscience) in the absence of stimulation. Cells were
fixed with 2% paraformaldehyde (PFA), permeabilized with 1%
saponin (Sigma-Aldrich), and stained with monoclonal antibodies
against IL-4 (BVD-24G2), IL-13 (eBio13A), and TNF (MP6-
XT22) (all eBioscience).
Dead cells were excluded using 7-AAD (eBioscience) or EMA
(Invitrogen). Samples were acquired on FACSCalibur and
FACSCantoII or sorted on FACSAriaII (BD) machines, and
analyzed with FlowJo software (Treestar).
To initiate growth factor deprivation-induced apoptosis,
BMMCs were extensively washed with PBS and cultured in
simple mast cell medium lacking IL-3 and SCF or supplemented
with 5 mg/mL anti-DNP IgE, 10 mg/mL LPS (both Sigma-
Aldrich), or 10 ng/mL IL-33 (PeproTech). Cell death was
quantified at the indicated time points after propidium iodide
staining (10 mg/mL; Sigma-Aldrich) and flow cytometric analysis.
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Cell cycle analysis was conducted by staining EtOH-fixed
BMMCs treated with 100 mg/mL RNase A using 50 mg/mL
propidium iodide (both Sigma-Aldrich).
Flow cytometric analysis of BAL fluid composition was per-
formed according to a recently described method [29].
To prepare skin single-cell suspensions, dissected ears were
digested in DMEM (Gibco) containing 25 mM Hepes (PAN),
0.05 mg/mL Liberase TM, 0.2 mg/mL DNase I (both Roche
Diagnostics), and 0.5 mg/mL Hyaluronidase (Sigma-Aldrich) at
37uC for 1 h and grinded through a 70 mm cell strainer (BD).
To prepare lung and MLN single-cell suspensions, lungs and
MLNs were digested using RPMI containing 0.02 mg/mL
Liberase TM and 10 U DNase (both Roche Diagnostics).
Immunofluoresence and Immunohistology
For whole-mount ear skin immunohistology, ears were sepa-
rated into dorsal and ventral sheets, and cartilage-free ear sheets
were fixed by floating on 1% PFA overnight at 4uC. For back skin
immunohistology, frozen 12 mm sections were thawed, air dried,
and fixed with methanol for 10 min at 220uC. Ear sheets and
back skin sections were blocked with 1% BSA and stained with a
rabbit anti-laminin antibody (gift from Michael Sixt) followed by
Cy3-conjugated anti-rabbit (Jackson ImmunoResearch), and
FITC-conjugated avidin (Zymed). Images were acquired with a
fluorescent microscope (Zeiss AxioImager Z1).
To study vascular permeability in the airways, mice were
sensitized (day 0; 1 mg/mouse, intratracheally (i.t.)) and challenged
(day 7; 10 mg/mouse; i.t.) with HDM. One hour after the i.t.
application, mice were injected intravenously with FITC+ 500 nm
microbeads (Invitrogen). Five minutes later mice were sacrificed,
blood was removed by perfusion with PBS followed by PFA, and
the trachea was isolated and cleaned. Blood vessels were visualized
by subsequent incubation of the trachea with 5% normal goat
serum in PBS with 3% Triton X-100 (PBS plus) (1 h, RT), rat anti-
mouse CD31 (1/500 in PBS plus, overnight, 4uC), and AF647
coupled goat anti-rat IgG (1/500 in PBS plus, 4 h, RT), separated
by several washes with PBS plus. Trachea whole mounts were
embedded in polyvinyl alcohol mounting medium (DABCO
Fluca). Beads and blood vessels were visualized by confocal
microscopy (Zeiss LSM 710).
Cell Culture
To generate BMMCs and PMCs, bulk bone marrow or
peritoneal cells were cultured in suspension in mast cell medium:
DMEM (Gibco) supplemented with 10% FCS (PAA), 2%
supernatant from X63/0 cells expressing IL-3 (gift from Ton
Rolink), 0.5% supernatant from CHO cells expressing SCF (gift
from Patrice Dubreuil), Glutamax (Gibco), Non Essential Amino
Acids (Gibco), 50 mM 2-mercaptoethanol (Merck), and 25 mM
Hepes (PAN). After 4 wk, BMMCs were cultured in mast cell
medium containing 1 mM 4-hydroxytamoxifen (Sigma-Aldrich) for
7 d to delete conditional alleles in vitro (BMMCs, KitCreERT2/+=Wt;
KitCreERT2/+A20+/F=A20wt/2; KitCreERT2/+A20F/F=A202/2; Kit-
CreERT2/+MyD88F/F=MyD882/2; KitCreERT2/+A20F/FMyD88F/F
=A202/2MyD882/2; PMCs, Mcpt5Cre=Wt; Mcpt5Cre A20F/F
=A202/2; Mcpt5Cre A20F/FMyD88F/F=A202/2MyD882/2).
Purity was checked based on the expression of FceRI and c-Kit
by flow cytometric analysis.
Murine synovial fibroblasts were isolated and cultured as
described previously [51] with slight modifications. In brief, ankle
joints were dissected, separated by cutting through the joint space,
and digested in DMEM (Gibco) containing 25 mM Hepes (PAN),
0.05 mg/mL Liberase TM, and 0.2 mg/mL DNase I (both Roche
Diagnostics) at 37uC for 1 h.
Signal Transduction and Western Blot
Whole cell lysates were prepared by lysing cells for 30 min on
ice in RIPA buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 1%
NP40, 1 mM EDTA, 0.25% Na-deoxycholate) supplemented with
10 mg/mL Aprotinin, 10 mg/mL Leupeptin, 0.1 mM Na3VO4,
1 mM PMSF, 10 mM NaF, 1 mM DTT, and 8 mM b-
Glycerophosphate after stimulation with LPS (Sigma-Aldrich),
TNFa, IL-1b, IL-33 (all PeproTech), or FceRI cross-linking (anti-
DNP IgE, SPE-7 supernatants; DNP-HSA, Sigma-Aldrich). PVDF
membranes were blotted with the following antibodies: A20, I-kBa
(both Santa Cruz), Bcl-xL (BD), AKT, phospho-AKT, ERK,
phospho-ERK, phospho-I-kBa, JNK, phospho-JNK, p38, phos-
pho-p38 (all Cell Signaling), MyD88 (Stressgen), IL-33 (Enzo Life
Sciences), and GAPDH (Calbiochem).
ELISA
TNF, IL-13, IL-1b (all PeproTech), IL-6, and IL-2 (both BD)
levels were determined by ELISA as recommended by the
manufacturer.
Real-Time PCR
RNA was isolated (USB) and reverse transcribed (Promega) for
quantitative real-time PCR using TaqMan Gene Expression
Assays (A1, Applied Biosystems) or Universal Probe Library (all
other genes, Roche Diagnostics) probes and primers as recom-
mended by the manufacturer.
DNA from sorted cells was isolated (Life Technologies), and
quantitative real-time PCR (10 min 95uC, 50 cycles: 10 s 95uC,
30 s 60uC, 1 s 72uC) was performed on DNA corresponding to
10,000 cells in a reaction volume of 20 mL containing 16TaqMan
Probe Master (Roche Diagnostics), 1 mM of each forward and
reverse primers (A20 locus a, 59-ACTGTTTGAAGCATGCA-
CGA-39; b, 59-ACAACCTGTCAAATCCATATTCAG-39; A20
deleted c, 59-AAATCTGGACAGCTGATTCCT-39; d, 59-CAA-
CATCTCAGAAGGACACCAT-39) and 0.1 mM TaqMan probe
#68 (A, Roche Diagnostics) or loxP probe (B, 59-6-FAM-
atAaCtTCgtatagCATaCattatac-BHQ-1-39; capital letters = LNA;
Eurogentec). In order to evaluate sensitivity of the real-time PCR,
we generated samples containing 1,000 (10%), 100 (1%), or 10
(0.1%) A202/2 BMMCs among 9,000, 9,900, or 9,990 A20F/F
splenocytes.
Mast Cell Degranulation
To induce degranulation, BMMCs and PMCs were loaded for 2
or 24 h with 1 mg/mL anti-DNP IgE (SPE-7 supernatant). After
washing in Tyrode’s buffer (10 mMHepes, pH 7.3, 135 mMNaCl,
5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose,
0.5 mg/mL BSA), cells were stimulated with the concentrations of
DNP–HSA indicated in the figure, 10 ng/mL IL-33, 10 mg/mL
LPS, or 500 ng/mL A23187 for 30 min. b-hexosaminidase activity
in supernatants and cell pellets solubilized with 0.5% Triton X-100
in Tyrode’s buffer were measured with p-nitrophenyl-N-acetyl-b-D-
glucosaminide (Sigma-Aldrich). To measure degranulation using
Annexin V binding, after 20 min of FceRI cross-linking, BMMCs
were washed in Annexin V binding buffer (25 mM Hepes, pH 7.2,
140 mM NaCl, 2.5 mM CaCl2), and Cy3-conjugated Annexin V
(gift from Dirk Mielenz) binding was analyzed by flow cytometric
analysis. To measure histamine release, PMCs were loaded 24 h
with 1 mg/mL anti-DNP IgE (SPE-7 supernatant), stimulated with
the concentrations of DNP–HSA indicated in the figure, 10 ng/mL
IL-33, 10 mg/mL LPS, or 500 ng/mL A23187 for 30 min, and
histamine levels were determined by EIA as recommended by the
manufacturer (Immunotech).
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Statistics
Statistical analysis of the results was performed by Log-rank
(Mantel-Cox) test, Mann-Whitney U test, Student’s t test, or by
one-way ANOVA followed by Tukey’s test. The p values are pres-
ented in figure legends where a statistically significant difference
was found.
Supporting Information
Figure S1 A20 expression is induced by IL-1b, LPS, IL-
33, and FceRI cross-linking in mast cells. (A) Wild-type and
A20-deficient BMMCs were stimulated with 10 ng/mL IL-1b for
3 h. A20 mRNA levels were determined by quantitative RT-PCR,
and protein levels were assessed by Western blotting. Changes in
transcript levels relative to unstimulated cells are shown after
normalization to PBGD. Data are means + SD (RT-PCR) from
three or representative (Western blot) of three independent
experiments. (B) Wild-type and A20-deficient BMMCs were
stimulated with 10 mg/mL LPS or 10 ng/mL IL-33 for the
indicated time intervals. To induce FceRI cross-linking, BMMCs
were loaded overnight with 1 mg/mL anti-DNP IgE and sub-
sequently stimulated for the indicated time intervals with 10 ng/mL
DNP–HSA. A20 protein levels were assessed by Western blotting
and are representative of three independent experiments. Quanti-
fications are shown in Figure 1A. (C) Representative dot plots
showing FceRI and c-Kit expression on BMMCs of the indicated
genotypes and proportions of FceRI+ and c-Kit+ cells. (D) Changes
in phosphorylated protein normalized to nonphosphorylated
protein levels and I-kBa levels normalized to GAPDH relative to
unstimulated wild-type BMMCs at time point 0 h are shown. Data
are geometric means from at least two independent experiments.
(TIF)
Figure S2 Mild cellular expansions in mast cell-specific
A20-deficient mice. (A) Representative immunofluorescence
images of dorsal skin sections: green, avidin-FITC; red, anti-
laminin; blue, DAPI; scale bar, 100 mm. Scatter plot shows mast
cell frequencies in dorsal skin sections. Individual data points
represent mean mast cell numbers in 10 fields of view per mouse.
Bars indicate means from at least six mice per genotype (Control, 7
Mcpt5Cre mice). (B) Dot plots showing proportions of cytokine
positive ex vivo isolated peritoneal mast cells (c-Kit+). Numbers
represent means 6 SD from at least eight mice per genotype
(Control, 9 Mcpt5Cre and 2 Cre2 littermates). (C) Western blot
analysis of A20 and MyD88 protein levels in PMCs of the
indicated genotypes. Data are representative of five independent
mast cell preparations (Control, 4Mcpt5Cre and 1 Cre2 littermate).
(D) Schematic representation of the A20 conditional allele before
and after Cre-mediated recombination (open squares, exons;
closed triangles, loxP sites) and location of real-time PCR primers
(a, b, A20 locus; c, d, deleted A20 locus) and probes (A, A20 locus;
B, deleted A20 locus). Ratios of genomic DNA corresponding to
the deleted A20 locus relative to the A20 locus (ratio (deleted:A20
locus) = 2Cp(A20 locus)-Cp(deleted)) were determined by quantitative
real-time PCR using locus-specific primers and fluorescent-labeled
TaqMan probes. Samples containing 10%, 1%, or 0.1% A202/2
BMMCs among 90%, 99%, or 99.9% A20F/F splenocytes were
used to determine the detection limit. Splenic T cells
(TCRb+B2202), B cells (TCRb2B220+), DCs (CD11chigh),
eosinophils (eos, CD11c2CD11b+SiglecF+SSC-Ahigh), mono-
cytes/macrophages (monos/macs, CD11c2CD11b+SiglecF2Gr-
1int), neutrophils (neutros, CD11c2CD11b+SiglecF2Gr-1high), and
peritoneal cavity macrophages (PC macs, CD11bhighc-Kit2) were
sorted from Mcpt5Cre A20F/F mice. Bars represent means + SD
from three mice (splenic subsets) or two mice (PC macs). (E)
Pictures of representative spleens from mice of the indicated
genotypes. Scatter plot shows absolute splenocyte numbers. Bars
are means from at least 13 mice per genotype (Control, 8 Mcpt5Cre
and 5 Cre2 littermates).
(TIF)
Figure S3 IL-33–induced airway inflammation is en-
hanced in Mcpt5Cre A20F/F mice. Mice were administered
100 ng IL-33 i.n. on 3 consecutive days. Scatter plots show
absolute lung cell numbers of Eos (eosinophils, SSChi, Ly6C+,
Ly6Gint, CD11b+, CD11c2), Monos (monocytes, SSCint, Ly6C+,
Ly6Glo, CD11b+, CD11c2), and Neutros (neutrophils, SSChi,
Ly6C+, Ly6Ghi, CD11b+, CD11c2) as identified by flow
cytometric analysis. Bars indicate means from three to six mice
per group (Control, 3 ‘‘PBS’’ and 5 ‘‘IL-33’’ Cre2 littermates).
*p,0.05 (Mann-Whitney test).
(TIF)
Figure S4 Mast cell-specific A20-deficient mice develop
exaggerated CIA. (A) Increase in paw thickness during CIA was
measured using an engineer’s micrometer. Data are means 6
SEM (for visual clarity instead of SD) from at least 10 mice per
genotype (Control, 16 Mcpt5Cre mice). (B) Histological sections of
ankle joints from CIA mice stained with hematoxylin and eosin.
(C) Serum TNF levels in CIA mice were measured by ELISA. Bars
indicate medians from at least 10 mice per genotype (Control, 13
Mcpt5Cre mice). (D) Scatter plots show absolute cell numbers of
total splenocytes, B cells (B220+), T cells (TCRb+), and CD4+ and
CD8+ T cell (TCRb+) subsets, and bars indicate means from at
least five mice per genotype (Control, 5 Mcpt5Cre mice) (effector-
like, CD44hiCD62Llo; memory-like, CD44hiCD62Lhi; naive,
CD44lo-intCD62Lhi). *p,0.05, **p,0.01 (one-way ANOVA).
(TIF)
Figure S5 Normal degranulation and immediate but
exacerbated late phase anaphylactic responses in the
absence of A20. (A) Data show dorsal skin temperatures over
time during PSA reactions measured with a thermography camera
and are means 6 SD from at least four mice per genotype
(Control, 5 Cre2 littermates). (B–E) BMMCs (B and C) and PMCs
(D and E) were loaded for 24 h with 1 mg/mL anti-DNP IgE and
subsequently stimulated for 30 min with the indicated concentra-
tions of DNP–HSA, 10 ng/mL IL-33, 10 mg/mL LPS, or 500 ng/
mL A23187. Degranulation was determined by measuring the
activity of b-hexosaminidase in supernatants and cell lysates. (F)
PMCs were loaded for 24 h with 1 mg/mL anti-DNP IgE and
subsequently stimulated for 30 min with the indicated concentra-
tions of DNP–HSA, 10 ng/mL IL-33, 10 mg/mL LPS, or 500 ng/
mL A23187. Histamine release was measured by EIA. Two
experiments are shown. Data are means + SD from six (B), five
(C), five (D), three (E), or three (F) independent mast cell
preparations. (G) Histological ear skin sections of late phase
PCA reactions stained with hematoxylin and eosin.
(TIF)
Figure S6 A20 is a key negative regulator of mast cell
activation. (A) BMMCs were stimulated for 6 h with 10 mg/mL
LPS or 10 ng/mL IL-33. TNF, IL-6, and IL-13 mRNA levels
were determined by quantitative RT-PCR. Changes in transcript
levels were calculated after normalization to PBGD. Data are
means + SD from four independent experiments. *p,0.05, **p,
0.01 (one-way ANOVA). (B) TNF, IL-6, and IL-13 secretion of
BMMCs stimulated for 6 h with 10 ng/mL IL-1b were measured
by ELISA. Data are means + SD from three independent
experiments. *p,0.05, **p,0.01 (one-way repeated measures
ANOVA). (C) BMMCs were stimulated as in (B). TNF, IL-6, and
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IL-13 mRNA levels were determined by quantitative RT-PCR.
Changes in transcript levels were calculated after normalization to
PBGD. Data are means + SD from three independent exper-
iments. *p,0.05, **p,0.01, ***p,0.001 (one-way ANOVA). (D)
BMMCs and PMCs were stimulated with 10 mg/mL LPS, 10 ng/
mL IL-33, or 40 nM Phorbol-12-myristate-13-acetate (PMA) and
400 nM Ionomycin (Iono) for 6 h. BMMCs and PMCs were
loaded for 2 h with 1 mg/mL anti-DNP IgE and subsequently
stimulated for 6 h with 10 ng/mL DNP–HSA. IL-2 secretion was
measured by ELISA. Data are means + SD from three
independent experiments (BMMCs) or three independent mast
cell preparations (PMCs). (E) IL-1b secretion of BMMCs
stimulated for 6 h as in (A) were measured by ELISA. Data are
means + SD from three independent experiments. (F) IL-13
secretion of BMMCs loaded for 2 h with 1 mg/mL anti-DNP IgE
and subsequently stimulated for 6 h with 10 ng/mL DNP–HSA
was measured by ELISA. Data are means + SD from three
independent experiments. (G) BMMCs were stimulated as in (F).
TNF, IL-6, and IL-13 mRNA levels were determined by
quantitative RT-PCR. Changes in transcript levels were calculated
after normalization to PBGD. Data are means + SD from three
independent experiments. *p,0.05, **p,0.01, ***p,0.001 (one-
way ANOVA).
(TIF)
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